XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research...
March 28 2017 - 7:00AM
XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and
development of therapeutic antibodies, announced today the
presentation of data from its PTH1R Monoclonal Antibodies Program.
The poster, which reports data from a pre-clinical study
investigating the efficacy of the Company’s anti-PTH1R antagonist
monoclonal antibody in reversing hypercalcemia, will be presented
at the American Association for Cancer Research annual meeting,
April 1-5, 2017, in Washington, DC.
Hypercalcemia is relatively common in patients with cancer,
occurring in up to 30 percent of casesi. Hypercalcemia often occurs
in patients with both solid tumors and hematologic malignancies due
to release of a protein that activates the parathyroid hormone
receptor (PTH1R) thereby leading to potentially dangerous calcium
levels. Malignancy often is evident clinically by the time it
causes hypercalcemia, and those patients often have a poor
prognosis.
“Our PTH1R program began as an endocrine program, but because of
its unique mechanism-of-action we believe it is also potentially
beneficial to oncology patients suffering from hypercalcemia,” said
Jim Neal, Chief Executive Officer of XOMA. “We seek partners who
have a deep commitment to and expertise in drug development. We
believe our PTH1R program could join the other antibodies in our
extensive licensing portfolio of fully funded programs that are
being advanced by partner companies to benefit patients suffering
from a wide range of health conditions.”
Poster Presentation DetailsAbstract
Title: Impacting Humoral Hypercalcemia of Malignancy (HHM)
and associated PTH1R-mediated morbidities: Characterization of an
anti-PTH1R antagonist monoclonal antibody to reverse
hypercalcemia
- Session: Late-Breaking Research (LB-306):
Experimental and Molecular Therapeutics 2
- Date: Wednesday, April 5, 2017, 8:00am to
12:00pm ET
- Location: Poster Section 34, Board 14
For additional information, please visit the AACR website:
www.aacr.org.
About XOMA’s PTH1R Monoclonal Antibodies
ProgramXOMA has developed several unique functional
antibody antagonists targeting PTH1R, a G-protein-coupled receptor
involved in the regulation of calcium metabolism. These antibodies
have shown promising efficacy in in vivo studies and potentially
could address high unmet medical needs, including primary
hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy
(HHM).
HHM is present in many advanced cancers and is caused by high
serum calcium due to increased levels of the PTH1R ligand
PTH-related peptide (PTHrP). Since current HHM treatments
often fall short and many cancer patients die from ‘metabolic
death’, PTH1R antibodies could prove beneficial for the treatment
of HHM.
About XOMA CorporationXOMA has an extensive
portfolio of products, programs, and technologies that are the
subject of licenses the Company has in place with other biotech and
pharmaceutical companies. Many of these licenses are the
result of the Company’s pioneering efforts in the discovery and
development of antibody therapeutics. There are more than 20
such programs that are fully funded by partners and could produce
milestone payments and royalty payments in the future. In order to
maximize its value in a licensing transaction, XOMA continues to
invest in X358, an allosteric monoclonal antibody that reduces
insulin receptor activity, as the antibody could have a major
impact on the treatment of hyperinsulinism. For more information,
visit www.xoma.com.
Forward-Looking StatementsCertain statements
contained in this press release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including
statements regarding: the potential of XOMA's portfolio of
partnered programs and licensed technologies generating substantial
milestone and royalty proceeds over time; positive momentum in
2017; the significant unmet therapeutic need for certain rare
medical conditions associated with hyperinsulinism; the continued
generation of antibodies by XOMA's proprietary phage display
libraries; the potential of IL-2 to provide opportunities to
improve patient outcomes; the potential for PTH1R to address high
unmet medical needs; XOMA's intent to license X213 and X358; the
possibility of the receipt of up to $4 million in additional sales
milestones under our agreements with HCRP; and statements that
otherwise relate to future periods. These statements are based on
assumptions that may not prove accurate, and actual results could
differ materially from those anticipated due to certain risks
inherent in the biotechnology industry and for companies engaged in
the development of new products in a regulated market. Potential
risks to XOMA meeting these expectations are described in more
detail in XOMA's most recent filing on Form 10-K and in other SEC
filings. Consider such risks carefully when considering XOMA's
prospects. Any forward-looking statement in this press release
represents XOMA's views only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. XOMA disclaims any obligation to update any
forward-looking statement, except as required by applicable
law.
i Stewart, AF. Hypercalcemia Associated with Cancer. N Engl
J Med 2005; 352:373-379.January 27, 2005DOI:
10.1056/NEJMcp042806.
Investor contact:
Luke Heagle
Pure Communications
+1 910-726-1372
lheagle@purecommunications.com
Media contact:
Colin Sanford
Pure Communications
+1 415-946-1094
csanford@purecommunications.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024